Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
OBJECTIVE
MicroRNA-128 (miR-128) has been identified as a negative regulator of malignant phenotypes of prostate cancer (PCa) cells. The aim of this study was to evaluate the prognostic implications of both tissue and serum levels of miR-128 expression in PCa patients undergoing radical prostatectomy.


METHODS
A series of 128 cases with PCa were evaluated for both tissue and serum levels of miR-128 expression by quantitative reverse-transcription PCR.


RESULTS
Compared with non-cancerous prostate tissues and normal sera, both tissue and serum levels of miR-128 expression were significantly decreased in PCa patients (both P<0.001). Importantly, there was a close correlation between tissue and serum levels of miR-128 expression in PCa patients (rs=0.808, P<0.001). Then, low miR-128 expression in both PCa tissues and patients' sera were dramatically associated with aggressive clinicopathological features, including advanced pathological stage (both P=0.001), positive lymph node metastasis (P=0.006 and 0.01, respectively), high preoperative PSA (both P=0.01) and positive angiolymphatic invasion (both P=0.02). Moreover, Kaplan-Meier survival analysis showed that low miR-128 expression in both PCa tissues and patients' sera were significantly associated with short biochemical recurrence (BCR)-free survival. Furthermore, multivariate analysis indicated that both tissue and serum levels of miR-128 expression were independent prognostic factors for BCR-free survival of PCa patients.


CONCLUSIONS
Our data suggest that the decreased expression of miR-128 in both tissue and serum samples of PCa patients may be associated with tumor malignant progression and BCR-free survival. Particularly, serum miR-128 may be developed as a novel noninvasive biomarker for PCa diagnosis and prognosis.
Department of Surgery, Xi'an Honghui Hospital Xi'an 710054, China.
Xiaoke
X
Sun
Department of Surgery, Xi'an Honghui Hospital Xi'an 710054, China.
Zhen
Z
Yang
Department of Infectious Diseases, Children's Hospital of Xi'an Xi'an 710003, China.
Yu
Y
Zhang
Department of Surgery, Xi'an Honghui Hospital Xi'an 710054, China.
Jing
J
He
Department of Surgery, Xi'an Honghui Hospital Xi'an 710054, China.
Feng
F
Wang
Department of Surgery, Xi'an Honghui Hospital Xi'an 710054, China.
Pengxiao
P
Su
Department of Surgery, Xi'an Honghui Hospital Xi'an 710054, China.
Juanli
J
Han
Department of Surgery, Xi'an Honghui Hospital Xi'an 710054, China.
Zhe
Z
Song
Department of Surgery, Xi'an Honghui Hospital Xi'an 710054, China.
Yanjiang
Y
Fei
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D016009:Chi-Square Distribution; D018450:Disease Progression; D018572:Disease-Free Survival; D015536:Down-Regulation; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D035683:MicroRNAs / Q000097:blood / Q000235:genetics*; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; C545189:MIRN128 microRNA, human; D035683:MicroRNAs
Prostate cancer; clinical pathology; microRNA-128; prognosis; serum